Healthcare

'The optimism around stability is probably higher than I've heard it has been at any other time in the last couple of years,' said Bain & Co's Nirad Jain as the firm releases new healthcare PE report.

Alphial produces glass primary packaging for pharmaceutical, chemical and cosmetic use.

OrganOx is an Oxford-based medtech company.

KabaFusion’s management team will remain significant investors and continue to lead the company, while Novo Holdings will exit its investment.

'Historically, everything required an operation,' said Lee Equity's Mark Gormley. 'Now, the new drugs and treatments are a lot more specific and sensitive.'

Capstone anticipates an influx of deal activity through the fourth quarter of 2025 and into 2026, as companies and fund managers digest recent economic and political volatility and these pressures subside.

Palamon, Bridgepoint and OTPP are among the firms investing in the dental sector.

Eversana is a Chicago-based provider of global services to the life sciences industry.

'We’re seeing a lot of capital needs not only across the therapeutic side of life sciences but also this biopharma ecosystem of all of the companies that serve these biopharma businesses,' said KKR's Ali Satvat.

The transaction is expected to close in the fourth quarter of 2025.